Ionis slashes Tryngolza's price to $40K—undercutting rival Redemplo by $20K annually
Ionis Pharmaceuticals has set the wholesale price of its new drug Tryngolza at $40,000 per year. This figure is far lower than the $20,000 ceiling initially announced and significantly undercuts a rival treatment. The new pricing will take effect from April 1, 2026. Tryngolza was originally expected to cost no more than $20,000 annually. However, Ionis has now confirmed a $40,000 price tag for both its approved use in familial chylomicronemia syndrome and its pending approval for severe hypertriglyceridemia. Regulators are set to decide on the latter indication by June 30, 2026.
The drug's pricing positions it well below Arrowhead's competing treatment, Redemplo, which costs $60,000 per year. Analysts have reacted positively to the announcement, with Barclays raising its price target for Tryngolza from $95 to $106 and lifting its 2034 revenue forecast to $4 billion. BofA Securities has kept a buy rating on Ionis, projecting peak sales of $2.4 billion even in a cautious scenario.
Meanwhile, William Blair has paused its financial model for Tryngolza to reassess following the unexpected price increase. Ionis shares currently trade around $73, leaving room for growth based on analyst expectations. The $40,000 annual price for Tryngolza will apply from April 2026, covering both current and potential future uses. Financial firms have adjusted their forecasts, with some seeing significant revenue potential. The drug's lower cost compared to Redemplo could influence its market position once both indications are approved.
